Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Clinical trial NCT05877963 · RECRUITING
Trial details
- NCT number
- NCT05877963
- Sponsor
- TG Therapeutics, Inc.
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-13
- Primary completion
- 2027-12-01
- Enrollment
- 800
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.